Low‐Dose Buprenorphine Induction in Pregnant and Postpartum Patients: A Retrospective Analysis of Protocol Implementation

ABSTRACT Background Low‐dose buprenorphine induction (LDBI) is a method using low doses of buprenorphine titrated to maintenance dosing. Literature on LDBI in pregnant and postpartum patients is limited to case series. The purpose of this study was to evaluate the implementation of an LDBI protocol, describe treatment outcomes of pregnant and postpartum patients with OUD who were treated with the protocol, and identify opportunities to improve this protocol. Methods An interdisciplinary team, including a clinical pharmacist, at a level IV maternity academic medical center developed and implemented an LDBI protocol. We performed a retrospective descriptive chart review of hospitalized pregnant and postpartum patients with opioid use disorder (OUD) at our institution. The primary outcome was successful LDBI, defined as reaching and discharging on goal dose buprenorphine without serious adverse effects. Secondary outcomes included adverse effects, protocol deviations, and characteristics that may predict success. Outpatient follow‐up was also described. Results Of the 78 patients included for analysis, 59 (75.6%) successfully completed LDBI. Of the 19 (24.4%) patients that did not, 8 (10.3%) left before achieving goal dose without documented reason, 6 (7.6%) had intolerable withdrawal symptoms, and 5 (5.1%) were discharged with plans to attempt LDBI at a later time. Of these 19 patients, 10 (52.6%) had successful LDBI at subsequent encounters with an overall success rate on serial inductions of 69 (88.5%). There were no recorded serious adverse medication events from the protocol that caused patient harm. Tobacco use disorder without nicotine replacement therapy was associated with unsuccessful LDBI. Flexible protocol deviations or modifications may increase LDBI success. Conclusion Inpatient LDBI at this level IV maternity care center resulted in high success rates and was well tolerated. Several opportunities for improvement in the implementation of inpatient LDBI were identified. Further research is needed on improving transitions of care to the outpatient setting.

Authors

Institutions

Publication Details

Journal
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
Published
2026-01-01
DOI
https://doi.org/10.1002/jac5.70173
Citations
1
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
41.85
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Low‐Dose Buprenorphine Induction in Pregnant and Postpartum Patients: A Retrospective Analysis of Protocol Implementation

Jessica Taylor Goldstein, L Leeman, Michael Herman, Alexandra Herman et al.
1 citations
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
Opioid Use Disorder Treatment
41.85
article

Low‐Dose Buprenorphine Induction in Pregnant and Postpartum Patients: A Retrospective Analysis of Protocol Implementation

Jessica Taylor Goldstein, L Leeman, Michael Herman, Alexandra Herman, Francheska Sevy Gurule, Kaitlyn Zbylut
article en
1 citations

Abstract

ABSTRACT Background Low‐dose buprenorphine induction (LDBI) is a method using low doses of buprenorphine titrated to maintenance dosing. Literature on LDBI in pregnant and postpartum patients is limited to case series. The purpose of this study was to evaluate the implementation of an LDBI protocol, describe treatment outcomes of pregnant and postpartum patients with OUD who were treated with the protocol, and identify opportunities to improve this protocol. Methods An interdisciplinary team, including a clinical pharmacist, at a level IV maternity academic medical center developed and implemented an LDBI protocol. We performed a retrospective descriptive chart review of hospitalized pregnant and postpartum patients with opioid use disorder (OUD) at our institution. The primary outcome was successful LDBI, defined as reaching and discharging on goal dose buprenorphine without serious adverse effects. Secondary outcomes included adverse effects, protocol deviations, and characteristics that may predict success. Outpatient follow‐up was also described. Results Of the 78 patients included for analysis, 59 (75.6%) successfully completed LDBI. Of the 19 (24.4%) patients that did not, 8 (10.3%) left before achieving goal dose without documented reason, 6 (7.6%) had intolerable withdrawal symptoms, and 5 (5.1%) were discharged with plans to attempt LDBI at a later time. Of these 19 patients, 10 (52.6%) had successful LDBI at subsequent encounters with an overall success rate on serial inductions of 69 (88.5%). There were no recorded serious adverse medication events from the protocol that caused patient harm. Tobacco use disorder without nicotine replacement therapy was associated with unsuccessful LDBI. Flexible protocol deviations or modifications may increase LDBI success. Conclusion Inpatient LDBI at this level IV maternity care center resulted in high success rates and was well tolerated. Several opportunities for improvement in the implementation of inpatient LDBI were identified. Further research is needed on improving transitions of care to the outpatient setting.

JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYVol. 9(1)
University of New Mexico Hospital (US), University of New Mexico (US)
Good health and well-being
Openalex Percentile: Top 2%
Opioid Use Disorder Treatment
41.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.